CareDx, Inc. (CDNA) Stock Price & How to Invest

CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community. Its core products are AlloSure, a next-generation-sequencing test that measures donor-derived cell-free DNA (dd-cfDNA) to detect kidney and heart transplant injury, and AlloMap, a long-established gene-expression test used by the large majority of U.S. heart-transplant centers. Around these tests the company layers patient-management software, pharmacy services, and a research-and-products franchise, positioning itself as an integrated transplant platform rather than a single-test lab.

The investment picture is one of a small-cap growth-plus-turnaround story. Revenue reaccelerated sharply in early 2026 (Q1 up about 39% year over year) and the company posted a rare quarterly profit, while raising full-year guidance and reshaping its portfolio through the Naveris oncology acquisition and the divestiture of its Lab Products unit. The bull case rests on durable testing-volume growth and expanding margins; the bear case centers on reimbursement risk and heavy reliance on the AlloSure and HeartCare franchises. The result is a name with genuine momentum but a valuation that already prices in continued execution.

Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.

6 analysts publish price targets on CDNA, averaging $43.67 against a $43.71 price as of August 2026, or -0.1%. The published targets run from $35.00 to $50.00, a moderate spread, and the ratings split 3 buy, 4 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CDNA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CareDx, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Testing-volume growth. Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. The most optimistic published target, $50.00, assumes this works close to its best case.

The case against. Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The most pessimistic target, $35.00, is roughly what CDNA is worth if this bites instead.

Read the full bull and bear case on CDNA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CareDx, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$413M
• Q1 2026 revenue: ~$118M (+39% YoY)
• 2026 revenue guidance: ~$447M to $465M
• 2026 adj. EBITDA guidance: ~$43M to $57M
• Net income (TTM): ~-$8M (Q1 2026 positive)
• Market cap: ~$1.1B

CDNA trades at roughly 2.5 to 3 times trailing revenue, a multiple that reflects reaccelerating growth and an early return to profitability rather than deep value. A cash cushion near $200 million and positive adjusted EBITDA guidance give it flexibility, but the trailing net loss means the market is paying for future execution. Reimbursement outcomes are the swing factor for whether the current multiple proves justified.

Other names that sit close to CDNA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CDNA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CDNA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CDNA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CDNA is a focused transplant-testing leader whose growth and newfound profitability are real, but reimbursement dependence and product concentration keep it a higher-risk position.

Whether CDNA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CDNA a buy or a sell?, and where the stock could go from here in the CDNA stock forecast.

For income investors, whether CDNA pays a dividend and how the payout looks is covered in does CDNA pay a dividend? And to weigh CDNA against a peer, read the full side-by-side comparisons: CDNA vs NSIT and CDNA vs GH.